COMMUNIQUÉS West-GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

04/11/2024 - 14:00

FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]

Allogene Therapeutics Announces Participation in November Investor Conferences

04/11/2024 - 14:30

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]

Vireo Growth Inc. Announces New $10 Million Convertible Debt Facility

04/11/2024 - 14:30

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), a cannabis company committed to providing safe access, quality products and great value to its [...]

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

04/11/2024 - 14:30

BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

04/11/2024 - 14:30

VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]

Parity Healthcare Analytics joins Synova to support safe, financially sustainable nurse staffing

04/11/2024 - 14:30

ROCKVILLE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Parity Healthcare Analytics has joined Synova Associates as a top-tier Premium Industry Partner, the two organizations announced today. Parity provides industry-leading [...]

IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies List for 2024

04/11/2024 - 14:30

WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the [...]

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

04/11/2024 - 14:30

Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif., [...]

Renovaro Issues Shareholder Letter and Provides Corporate Update

04/11/2024 - 14:31

LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) , a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief [...]

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

04/11/2024 - 14:39

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from [...]

Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

04/11/2024 - 14:57

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) [...]

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

04/11/2024 - 15:00

Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with azelaprag [...]

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market

04/11/2024 - 15:00

Clearance expands indication for use from 11-18 year olds to 8-21 year olds; and from 3 devices, not to exceed 4 weeks, to 1 device per week for 4 weeks CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“ [...]

SoldierStrong, USC Institute for Creative Technologies Sign License Agreement for Battle Buddy

04/11/2024 - 15:00

STAMFORD, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SoldierStrong, a national nonprofit dedicated to helping veterans take their next steps forward in life after service through the donation of revolutionary medical [...]

VitalHub Announces Q3 2024 Conference Call Date

04/11/2024 - 15:00

TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it will release its financial results for its third quarter 2024 ended [...]

AAMI Updates Standard on Hospital use of Ethylene Oxide, Chemical Sterilization

04/11/2024 - 15:06

AAMI ST58 Will Help Prevent Healthcare Associated Infections Arlington, VA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Regulatory and safety concerns are currently a pressing issue for hospital employees who use ethylene oxide ( [...]

Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award

04/11/2024 - 15:30

SHANGHAI and SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Hua Medicine , a pioneering biotechnology company, continues to lead the charge in diabetes treatment innovation. As global diabetes rates rise, Hua Medicine [...]

KFSHRC Wins Gold and Four Bronze Stevie® Awards for Innovative Recruitment Strategies

04/11/2024 - 15:51

Attracting 4647 Talents Locally and Globally Over Two Years RIYADH, Saudi Arabia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has been awarded a Gold and four Bronze [...]

Nous sommes maintenant Percée DT1 – l’organisation auparavant connue sous le nom de FRDJ Canada change de nom pour reconnaître l'impact du diabète de type 1 sur les Canadiennes et Canadiens de tous âges

04/11/2024 - 16:00

La principale organisation de recherche et de défense d’intérêts pour le diabète de type 1 (DT1) dévoile sa nouvelle identité afin de mieux refléter la communauté qu'elle sert tout en s'efforçant d'accélérer les percées [...]